본문으로 건너뛰기
← 뒤로

Lost to Follow-up: Social Determinants and Patient Perceptions in Lung Cancer Screening Adherence.

Clinical lung cancer 2026 Vol.27(3) p. 65-75

Azuma M, Nguyen A, Tompkins AK, Chin K, Walker B, Matta R, Yu D, Erkmen CP

📝 환자 설명용 한 줄

[BACKGROUND] Lung cancer screening (LCS) with Low-Dose Computed Tomography (LDCT) significantly reduces cancer mortality but remains substantially underutilized.

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 표본수 (n) 236
  • p-value P < .01
  • p-value P = .02
  • 연구 설계 cohort study

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Azuma M, Nguyen A, et al. (2026). Lost to Follow-up: Social Determinants and Patient Perceptions in Lung Cancer Screening Adherence.. Clinical lung cancer, 27(3), 65-75. https://doi.org/10.1016/j.cllc.2025.10.004
MLA Azuma M, et al.. "Lost to Follow-up: Social Determinants and Patient Perceptions in Lung Cancer Screening Adherence.." Clinical lung cancer, vol. 27, no. 3, 2026, pp. 65-75.
PMID 41188109

Abstract

[BACKGROUND] Lung cancer screening (LCS) with Low-Dose Computed Tomography (LDCT) significantly reduces cancer mortality but remains substantially underutilized. This study examines how social determinants of health (SDOH), including financial concerns, transportation barriers, and patient-provider trust, influence adherence to annual LCS.

[METHODS] A prospective cohort study was conducted at an urban, safety-net academic health system. Participants who initially underwent LDCT but failed to adhere to annual follow-up were surveyed, assessing demographics, financial and transportation concerns, patient-provider relationships, and experiences of racial discrimination. Data was analyzed using descriptive statistics, chi-square tests, and Spearman correlations.

[RESULTS] Among surveyors (n = 236), cost concerns (54.4%) and access to transportation (13.3%) were significant barriers to LCS adherence. Access to transportation was more limited for non-White (22.2%) and female (18.4%) populations, compared to White (6.5%, P < .01) and male (7.1%, P = .02) populations. However, there was no difference in cost concerns (P = .50, P = .89). Additionally, non-White (4.51/5 vs. 4.26/5, P < .01) and female (4.44/5 vs. 4.31/5, P = .04) patients reported higher levels of trust and comfort with providers comparing to their counter cohorts. Perceived racial discrimination in healthcare remained higher in non-White participants (1.53/5 vs. 1.25/5, P < .01) without effect in gender cohorts (P = .24).

[CONCLUSIONS] LCS can decrease the chance of lung cancer death among eligible individuals but is drastically underutilized. Most people not adhering to LCS cited cost concerns, despite coverage by insurers. Patient-provider trust can be leveraged to assess and address individual barriers to LCS.

MeSH Terms

Humans; Lung Neoplasms; Male; Female; Middle Aged; Aged; Prospective Studies; Social Determinants of Health; Follow-Up Studies; Early Detection of Cancer; Patient Compliance; Tomography, X-Ray Computed; Trust